Puromycin hydrochloride
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-05839 |
| CAS | 3506-23-8 |
| Molecular Weight | 507.97 |
| Molecular Formula | C22H29N7O5.HCl |
| Purity | ≥95% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-05839 | 25 mg | $199 | In stock |
Online Inquiry
Add to cartDescription
Puromycin hydrochloride is the hydrochloride salt of puromycin, a nucleoside antibiotic isolated from Streptomyces alboniger. It is an anti-trypanosomiasis drug with antibiotic activity.
Specification
| Related CAS | 53-79-2 (free base) 58-58-2 (dihydrochloride) |
| Synonyms | 3'-Deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine hydrochloride (1:1); Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-, hydrochloride (1:1); Stylomycin hydrochloride; Achromycin hydrochloride; CL 13900 hydrochloride; P638 hydrochloride; Adenosine, 3'-(α-amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyl-, monohydrochloride, L- |
| Storage | Store at -20°C under inert atmosphere |
| IUPAC Name | (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide;hydrochloride |
| Canonical SMILES | CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl |
| InChI | InChI=1S/C22H29N7O5.ClH/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12;/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32);1H/t14-,15+,16+,18+,22+;/m0./s1 |
| InChI Key | MXJUOYXSYWPMAR-IHFNEQFUSA-N |
Properties
| Appearance | White to Off-white Solid |
| Antibiotic Activity Spectrum | Neoplastics (Tumor); Bacteria |
| Solubility | Soluble in DMSO (Slightly), Ethanol (Slightly, Sonicated), Water (Slightly) |
Reference Reading
1. Effects of tacrolimus on autophagy protein LC3 in puromycin-damaged mouse podocytes
Li Yu, Yao Zhang, Guo-Sheng Liu, Lin Ge, Sheng-You Yu, Xiao-Qing Yang, Zhi-Hong Hao J Int Med Res . 2020 Dec;48(12):300060520971422. doi: 10.1177/0300060520971422.
Objective:To investigate the mechanism through which tacrolimus, often used to treat refractory nephropathy, protects against puromycin-induced podocyte injury.Methods:Anin vitromodel of puromycin-induced podocyte injury was established by dividing podocytes into three groups: controls, puromycin only (PAN group), and puromycin plus tacrolimus (FK506 group). Podocyte morphology, number, apoptosis rate and microtubule associated protein 1 light chain 3 alpha (LC3) expression were compared.Results:Puromycin caused podocyte cell body shrinkage and loose intercellular connections, but podocyte morphology in the FK506 group was similar to controls. The apoptosis rate was lower in the FK506 group versus PAN group. The low level of LC3 mRNA observed in untreated podocytes was decreased by puromycin treatment; however, levels of LC3 mRNA were higher in the FK506 group versus PAN group. Although LC3-I and LC3-II protein levels were decreased by puromycin, levels in the FK506 group were higher than the PAN group. Fewer podocyte autophagosomes were observed in the control and FK506 groups versus the PAN group. Cytoplasmic LC3-related fluorescence intensity was stronger in control and FK506 podocytes versus the PAN group.Conclusions:Tacrolimus inhibited puromycin-induced mouse podocyte damage by regulatingLC3expression and enhancing autophagy.
2. Active Ribosome Profiling with RiboLace
Ewout J N Groen, Marta Marchioretto, Gabriella Viero, Divya T Kandala, Laura Pasquardini, Paola Bernabò, Graziano Guella, Massimiliano Clamer, Luca Minati, Elena Perenthaler, Daniele Gubert, Thomas H Gillingwater, Alessandro Quattrone, Rodolfo F Gómez-Biagi, Toma Tebaldi, Fabio Lauria Cell Rep . 2018 Oct 23;25(4):1097-1108.e5. doi: 10.1016/j.celrep.2018.09.084.
Ribosome profiling, or Ribo-seq, is based on large-scale sequencing of RNA fragments protected from nuclease digestion by ribosomes. Thanks to its unique ability to provide positional information about ribosomes flowing along transcripts, this method can be used to shed light on mechanistic aspects of translation. However, current Ribo-seq approaches lack the ability to distinguish between fragments protected by either ribosomes in active translation or inactive ribosomes. To overcome this possible limitation, we developed RiboLace, a method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. RiboLace is fast, works reliably with low amounts of input material, and can be easily and rapidly applied both in vitro and in vivo, thereby generating a global snapshot of active ribosome footprints at single nucleotide resolution.
3. Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies
Jessica Williams, Rohit Singh, Robert Vince Eur J Med Chem . 2017 Oct 20;139:325-336. doi: 10.1016/j.ejmech.2017.07.048.
Substantial progress has been described in the study of puromycin and its analogs for antibiotic properties. However, the peptidase inhibitory activity of related analogs has not been explored as extensively. Specifically, inhibiting aminopeptidases for achieving antitumor effect has been sparsely investigated. Herein, we address this challenge by reporting the synthesis of a series of analogs based on the structural template of puromycin. We also present exhaustive biochemical and in vitro analyses in support of our thesis. Analyzing the structure-activity relationship revealed a steric requirement for maximum potency. Effective inhibitors of Puromycin-Sensitive Aminopeptidase (PSA) are disclosed here. These potential therapeutic agents display superior in vitro antitumor potency against two leukemic cell lines, as compared to known inhibitors of aminopeptidases.
Recommended Products
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
